MinvervaX CFO & CDO Appointment

19/04/2026

MinvervaX CFO & CDO Appointment MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans...

Treetop Meeting

27/08/2025

We usually do not share updates from internal meetings – but this was too fantastic not to share. A full day meeting in the midst of branches of +100 year old oaks and beech trees overlooking Isefjorden in “the treetop huts” at Ryegaard & Trudsholm Godser....

Hans T. Scambye joins Sunstone as Venture Partner

28/01/2025

Hans T. Scambye joins Sunstone as Venture Partner Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans...

Neumirna Therapeutics secures euro 20M in Series A financing

08/01/2025

Neumirna Therapeutics secures euro 20M in Series A financing Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

25/03/2024

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive...